Suppr超能文献

[Not Available].

作者信息

Filella Xavier, Guañabens Núria

机构信息

Servicio de Bioquímica y Genética Molecular (CDB), Hospital Clinic, IDIBAPS, Hospital Clínic de Barcelona, Barcelona, España.

Servicio de Reumatología, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, España.

出版信息

Adv Lab Med. 2023 Jul 24;5(1):15-23. doi: 10.1515/almed-2023-0041. eCollection 2024 Mar.

Abstract
摘要

相似文献

1
[Not Available].
Adv Lab Med. 2023 Jul 24;5(1):15-23. doi: 10.1515/almed-2023-0041. eCollection 2024 Mar.

本文引用的文献

1
Bone turnover markers to monitor oral bisphosphonate therapy.
Cleve Clin J Med. 2023 Jan 3;90(1):26-31. doi: 10.3949/ccjm.90a.22002.
2
Bone Turnover Markers: Basic Biology to Clinical Applications.
Endocr Rev. 2023 May 8;44(3):417-473. doi: 10.1210/endrev/bnac031.
3
New Emerging Biomarkers for Bone Disease: Sclerostin and Dickkopf-1 (DKK1).
Calcif Tissue Int. 2023 Feb;112(2):243-257. doi: 10.1007/s00223-022-01020-9. Epub 2022 Sep 27.
4
Current use of bone turnover markers in the management of osteoporosis.
Clin Biochem. 2022 Nov-Dec;109-110:1-10. doi: 10.1016/j.clinbiochem.2022.09.002. Epub 2022 Sep 9.
5
The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.
Calcif Tissue Int. 2023 Feb;112(2):258-270. doi: 10.1007/s00223-022-00987-9. Epub 2022 Jun 4.
6
A Systematic Review of the Circadian Rhythm of Bone Markers in Blood.
Calcif Tissue Int. 2023 Feb;112(2):126-147. doi: 10.1007/s00223-022-00965-1. Epub 2022 Mar 19.
7
Low serum osteocalcin levels are associated with diabetes mellitus in glucocorticoid treated patients.
Osteoporos Int. 2022 Mar;33(3):745-750. doi: 10.1007/s00198-021-06167-z. Epub 2021 Sep 24.
8
An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk.
Front Physiol. 2021 Mar 9;12:632260. doi: 10.3389/fphys.2021.632260. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验